Investment Rating - The investment rating for the company is "Buy" (maintained) [4][11] Core Insights - The company reported a revenue of 16.19 billion yuan for 2025, representing a year-on-year growth of 7.05%. However, the net profit attributable to shareholders decreased by 8.46% to 1.36 billion yuan [5] - The company has shown strong performance in new retail and e-commerce, with significant growth in sales from these channels, particularly through partnerships with platforms like Hema and Meituan [7] - The introduction of new products has met expectations, contributing positively to market feedback and sales [7] Financial Performance Summary - Revenue projections for the company are as follows: 15.13 billion yuan in 2024, 16.19 billion yuan in 2025, 17.47 billion yuan in 2026, 18.81 billion yuan in 2027, and 20.11 billion yuan in 2028, with growth rates of 8%, 7%, 8%, 8%, and 7% respectively [4] - The net profit attributable to shareholders is forecasted to be 1.49 billion yuan in 2024, 1.36 billion yuan in 2025, 1.69 billion yuan in 2026, 1.87 billion yuan in 2027, and 1.99 billion yuan in 2028, with growth rates of 0%, -8%, 24%, 11%, and 7% respectively [4] - The earnings per share (EPS) are projected to be 5.06 yuan in 2024, 4.08 yuan in 2025, 5.06 yuan in 2026, 5.60 yuan in 2027, and 5.98 yuan in 2028 [4] Market and Product Insights - The company has expanded its product offerings, including frozen prepared foods and baked goods, which have contributed to revenue growth [7] - The company is focusing on high-margin new products and enhancing its marketing strategies to support distributor upgrades and deepen partnerships with new retail channels [7] - The gross margin for 2025 is expected to decrease by 1.7 percentage points to 21.60%, primarily due to increased raw material costs [7]